Abstract:The refractoriness of many solid tumors to cytotoxic chemotherapy has led to the exploration of new therapeutic modalities, including immunotherapy. Immunotherapy does not have a direct cytotoxic effect on the cancer cell but is an attempt to promote rejection of the tumor by the host, chiefly through the cellular arm of the immune system. The clinical success with immunotherapy (primarily adoptive immunotherapy) among patients with unresectable malignant melanoma and cancer of the kidney has not been marked by the large numbers of patients responding but by occasional dramatic effectiveness of therapy for these cancers, which usually are refractory to chemotherapy. Long-lasting responses and even complete disappearance of all known metastases are possible for a small percentage of patients with melanoma or renal cell carcinoma who undergo immunotherapy. A reasonable approach for patients with good performance status (no symptoms or ambulatory with symptoms but not bedridden) is entrance to clinical trials, especially trials examining adoptive or active immunotherapy for melanoma or adoptive immunotherapy for renal cancer. The overall treatment of patients with cancer has changed. Primary-care physicians detect almost all cancers. The days when "taking it out" is the best we could offer a patient are over. As we learn more about the use of adjuvant or neoadjuvant chemotherapy and radiation therapy, it is likely one or both of these modalities will be incorporated into the treatment of additional solid tumors previously managed solely with surgical resection. Increasingly, additional therapy is being given for earlier-stage disease as we define how to maximize the potential for cure with minimal toxicity. Many new therapies are on the horizon, including the use of noncytotoxic treatments as an adjunct to a surgical procedure. Such therapies include the use of angiogenesis inhibitors, tumor vaccines, and immunotherapy. Now and in the future, patients will be best served when treated in an environment that can integrate medical, surgical, and radiation oncology actively.

Laser Immunotherapy for Advanced Solid Tumors

Laser Assisted Immunotherapy (lit) for Chemotherapy-Resistant Neoplasms: Recent Case Reports

Treatment of Advanced Melanoma with Laser Immunotherapy and Ipilimumab

Mechanism Study of Tumor-Specific Immune Responses Induced by Laser Immunotherapy

The immunological response created by interstitial and non-invasive laser immunotherapy

Anti-Tumor Responses Induced by Laser Irradiation and Immunological Stimulation Using A Mouse Mammary Tumor Model

Laser Immunotherapy:a Novel Modality for Cancer Treatment

Immunotherapy for Skin Cancer

Laser Immunotherapy for Metastatic Pancreatic Cancer (conference Presentation)

Neutrophil Infiltration and Whole-Cell Vaccine Elicited by N-dihydrogalactochitosan Combined with NIR Phototherapy to Enhance Antitumor Immune Response and T Cell Immune Memory

Histological and Morphological Studies of Immune Responses Induced by Laser Immunotherapy

Photothermal Therapy Improves the Efficacy of Topical Immunotherapy Against Melanoma

Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies

Effects of Laser Immunotherapy on Late-Stage, Metastatic Breast Cancer Patients in A Phase Ii Clinical Trial

Treatment of pancreatic tumors using combination of laser irradiation and immunological stimulation (Conference Presentation)

Localized ablative immunotherapy drives de novo CD8 + T-cell responses to poorly immunogenic tumors

Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Temperature Distribution in Target Tumor Tissue and Photothermal Tissue Destruction During Laser Immunotherapy

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Laser Immunotherapy for Cutaneous Squamous Cell Carcinoma with Optimal Thermal Effects to Enhance Tumour Immunogenicity